sc13g

OMB APPROVAL

OMB Number: 3235-0145

Expires: December 31, 2005

Estimated average burden
hours per response...11


Schedule 13G					Page 1 of 4

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).


13G
CUSIP No. 46119F 10 7					Page 2 of 4

	1.	Name of Reporting Person: David G. Nance			I.R.S. Identification Nos. of above persons (entities only):

	2.	Check the Appropriate Box if a Member of a Group:
		(a)	o
		(b)	o

	3.	SEC Use Only:

	4.	Citizenship or Place of Organization: United States

Number of Shares Beneficially Owned by Each Reporting Person With
			5.	Sole Voting Power: 2,852,695

			6.	Shared Voting Power: 0

			7.	Sole Dispositive Power: 2,852,695

			8.	Shared Dispositive Power: 0

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 2,852,695

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares: o

	11.	Percent of Class Represented by Amount in Row (9): 10.5%

	12.	Type of Reporting Person: IN

Item 1.

(a) Introgen Therapeutics, Inc., a Delaware corporation

(b) 301 Congress Ave., Suite 1850, Austin, TX 78701

Item 2.

(a) David G. Nance

(b) 301 Congress Ave., Suite 1850, Austin, TX 78701

(c) USA

(d) Common Stock, par value $0.001 per share

(e) 46119F 10 7

Item 3. NOT APPLICABLE

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owed: 2,852,695

(b) Percent of class: 10.5%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote 2,852,695

(ii) Shared power to vote or to direct the vote 0

(iii) Sole power to dispose or to direct the disposition of 2,852,695

(iv) Shared power to dispose or to direct the disposition of 0

Item 5. Ownership of Five Percent or Less of a Class

NOT APPLICABLE

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Reporting Person has the right to receive and the power to direct the receipt of dividends from or the proceeds from the sale of 2,215,605 shares by virtue of his position as the Chief Executive Officer and sole stockholder of Domecq Technologies and as the Chief Executive officer of each of Developtech Resources Corporation and Debouchement, Ltd.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

NOT APPLICABLE

Item 8. Identification and Classification of Members of the Group

NOT APPLICABLE

Item 9. Notice of Dissolution of Group

NOT APPLICABLE


Schedule 13G					Page 4 of 4

Item 10. Certification

(a) Not applicable.

(b) Not applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


		February 17, 2004

		Date

		/s/ David G. Nance

		Signature

		DAVID G. NANCE

		Name/Title

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Table of Contents

Table of Contents

Table of Contents

Table of Contents


	Item 1.
	Item 2.
	Item 3. NOT APPLICABLE
	Item 4. Ownership
	Item 5. Ownership of Five Percent or Less of a Class
	Item 6. Ownership of More than Five Percent on Behalf of Another Person
	Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
	Item 8. Identification and Classification of Members of the Group
	Item 9. Notice of Dissolution of Group
	Item 10. Certification
SIGNATURE

	(a)		Introgen Therapeutics, Inc., a Delaware corporation

	(b)		301 Congress Ave., Suite 1850, Austin, TX 78701

	(a)		David G. Nance

	(b)		301 Congress Ave., Suite 1850, Austin, TX 78701

	(c)		USA

	(d)		Common Stock, par value $0.001 per share

	(e)		46119F 10 7

	(a)		Amount beneficially owed: 2,852,695

	(b)		Percent of class: 10.5%

	(c)		Number of shares as to which the person has:

	(i)		Sole power to vote or to direct the vote 2,852,695

	(ii)		Shared power to vote or to direct the vote 0

	(iii)		Sole power to dispose or to direct the disposition of 2,852,695

	(iv)		Shared power to dispose or to direct the disposition of 0